Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women.

Khuong-Josses MA, Azerad D, Boussaïri A, Ekoukou D.

HIV Clin Trials. 2007 Jul-Aug;8(4):254-5. No abstract available.

PMID:
17720666
2.
3.

Steady-state lopinavir levels in third trimester of pregnancy.

Lyons F, Lechelt M, De Ruiter A.

AIDS. 2007 May 11;21(8):1053-4.

PMID:
17457104
4.

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP.

Antimicrob Agents Chemother. 2012 Feb;56(2):816-24. doi: 10.1128/AAC.05186-11. Epub 2011 Nov 21.

5.

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.

Cressey TR, Van Dyke R, Jourdain G, Puthanakit T, Roongpisuthipong A, Achalapong J, Yuthavisuthi P, Prommas S, Chotivanich N, Maupin R, Smith E, Shapiro DE, Mirochnick M; IMPAACT P1032 Team.

Antimicrob Agents Chemother. 2009 May;53(5):2189-91. doi: 10.1128/AAC.01091-08. Epub 2009 Feb 23.

6.

[Usefulness of plasma lopinavir levels during pregnancy].

Aragonès-Eroles AM, Puig-Ganau T, Cano-Marron SM, Schoenenberger-Arnaiz JA.

Enferm Infecc Microbiol Clin. 2013 Dec;31(10):699-700. doi: 10.1016/j.eimc.2013.03.015. Epub 2013 May 4. Spanish. No abstract available.

PMID:
23648368
7.

Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.

Morello J, Soriano V, Blanco F, Rubio AJ, Jiménez-Nácher I, Rodríguez-Nóvoa S.

Drug Metab Lett. 2009 Apr;3(2):67-9.

PMID:
19601866
8.

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.

Lambert JS, Else LJ, Jackson V, Breiden J, Gibbons S, Dickinson L, Back DJ, Brennan M, Connor EO, Boyle N, Fleming C, Coulter-Smith S, Khoo SH.

HIV Med. 2011 Mar;12(3):166-73. doi: 10.1111/j.1468-1293.2010.00865.x. Epub 2010 Aug 18.

9.

Lopinavir protein binding in HIV-1-infected pregnant women.

Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team.

HIV Med. 2010 Apr;11(4):232-8. doi: 10.1111/j.1468-1293.2009.00767.x. Epub 2009 Dec 3.

10.

Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.

van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham K.

Antivir Ther. 2009;14(7):1001-4. doi: 10.3851/IMP1410.

PMID:
19918104
11.

Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.

Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV.

J Clin Pharmacol. 2011 Dec;51(12):1665-73. doi: 10.1177/0091270010388650. Epub 2011 Jan 13.

12.

Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.

Hull MW, Harris M, Lima V, Guillemi S, Harrigan PR, Montaner JS.

J Clin Pharmacol. 2009 Feb;49(2):155-61. doi: 10.1177/0091270008329550.

PMID:
19179294
13.

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities.

Peixoto MF, Pilotto JH, Stoszek SK, Kreitchmann R, Mussi-Pinhata MM, Melo VH, João EC, Ceriotto M, Souza Rda S, Read J.

Braz J Infect Dis. 2011 May-Jun;15(3):253-61.

14.

Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).

Chachad S, Gogtay J, Malhotra G, Purandare S.

J Pharm Sci. 2010 Feb;99(2):572-3; author reply 574. doi: 10.1002/jps.21852. No abstract available.

PMID:
19718766
15.

Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.

[No authors listed]

TreatmentUpdate. 2008 Mar;20(2):5-6. No abstract available.

PMID:
18661644
16.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62.

17.

A king in the CASTLE? Optimum initial HIV protease inhibitor.

Torti C, Frank I.

Lancet. 2008 Aug 23;372(9639):604-6. doi: 10.1016/S0140-6736(08)61253-2. No abstract available.

PMID:
18722849
18.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
19.

Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

Calza L, Manfredi R, Trapani F, Salvadori C, Colangeli V, Borderi M, Grossi G, Motta R, Viale P.

Scand J Infect Dis. 2012 May;44(5):381-7. doi: 10.3109/00365548.2011.642306. Epub 2012 Jan 21.

PMID:
22263609
20.

Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M.

Ther Drug Monit. 2008 Oct;30(5):604-10. doi: 10.1097/FTD.0b013e3181867a6e.

PMID:
18728627
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk